*Department of Ophthalmology, Rabin Medical Center, Petah-Tikva, Israel;
†Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel;
‡Metropolitan Eye Research and Surgery Institute, Palisades Park, NJ;
§Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, MA;
¶Ocular Immunology and Uveitis Foundation (OIUF), Waltham, MA;
‖Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO;
**Department of Ophthalmology and Visual Sciences, The Ohio State University Wexner Medical Center, Columbus, OH;
††Department of Ophthalmology, Harvard Medical School, Boston, MA; and
‡‡Institute of Ophthalmology and Visual Science, New Jersey Medical School, Rutgers University, Newark, NJ.
Correspondence: Yael Sharon, MD, Department of Ophthalmology, Rabin Medical Center, 39 Jabotinski St, Petah Tikva 49100, Israel (e-mail: [email protected]).
Supported, in part, by Mallinckrodt Pharmaceuticals as a medical writing grant (#1686).
D. S. Chu serves as a speaker for Abbvie and Novartis and as a consultant for Aldeyra Therapeutics Dompé, Mallinckrodt and Santen Pharmaceuticals. S. D. Anesi serves as a consultant for Mallinckrodt and Santen Pharmaceuticals, Allakos, Eyepoint, and Takeda and as a speaker for AbbVie, Mallinckrodt, and Eyepoint. A. J. W. Huang serves as a speaker for Mallinckrodt. C. S. Foster serves as a consultant for Aldeyra Therapeutics, Allakos, Bausch & Lomb Surgical, Eyegate Pharma, Genentech, Novartis, and pSivida and as a speaker for Alcon and Allergan and Mallinckrodt pharmaceuticals. The remaining authors have no conflicts of interest to disclose.
